Last updated: February 25, 2026
What Is NDC 60505-4378?
NDC 60505-4378 refers to a specific pharmaceutical product registered with the U.S. Food and Drug Administration (FDA). Based on available data, this NDC corresponds to SNDX-5613, an investigational drug developed by Syndax Pharmaceuticals, intended for hematologic malignancies, specifically acute myeloid leukemia (AML), and currently in clinical development phases.
Market Context and Current Status
Development and Regulatory Stage
- Phase of Clinical Development: Phase 1/2 trials initiated in 2020, with ongoing assessments.
- Regulatory Pathway: No FDA approval granted yet; potential approval anticipated within 2-3 years pending successful trial data.
- Market Exclusivity: Not yet granted; patent protections likely to be filed post-approval.
Competitive Landscape
- Major Competitors:
- IDH inhibitors: AG-120 (Vorasidenib), IDHIFA (Enasidenib)
- FLT3 inhibitors: Gilteritinib (Xospata), Midostaurin (Rydapt)
- Emerging therapies targeting similar pathways in AML.
- Market Size (AML):
- US market estimated at $1.2 billion in 2022.
- Growth rate projected at 8-10% annually through 2027.
- Market Drivers:
- Increasing incidence of AML (around 20,000 new cases annually in the US).
- Improved survival with targeted therapies.
Pricing Considerations
- Current Pricing of Similar Agents:
- Enasidenib: Approximately $28,000/month.
- Gilteritinib: Approximately $16,000/month.
- Potential Pricing for NDC 60505-4378:
- Expected to be in the $20,000 – $30,000/month range, contingent on efficacy, dosing, and competitive factors.
- Pricing pressures may arise from generic or biosimilar entries post-patent expiry.
Market Entry and Revenue Projections
Adoption Timeline
- Regulatory approval forecasted within 2-3 years.
- First-year sales estimate: $50–$100 million, depending on clinical success and market penetration.
- Five-year revenue projection: $500 million to $1 billion, assuming broad adoption in eligible AML patients.
Pricing Strategy Impact
| Scenario |
Price per Month |
Estimated Year 1 Revenue |
Notes |
| High Price Scenario (>$25,000) |
$28,000 |
~$120 million |
Premium pricing for targeted efficacy; limited patient pool |
| Moderate Price Scenario (~$20,000) |
$20,000 |
~$85 million |
Competitive positioning; wider acceptance |
| Low Price Scenario (~$15,000) |
$15,000 |
~$65 million |
Market share driven by affordability |
Market Share Expectations
- Initial market share limited to 5-10% of eligible AML patients due to the specialized indication.
- Market penetration could increase with positive trial data, expanded indications, and reputation.
Price Trajectory and Long-term Outlook
- Pre-approval Phase: Prices are driven by clinical trial costs, investor expectations, and anticipated market positioning.
- Post-approval:
- Prices tend to stabilize within the $20,000–$30,000/month range.
- Biosimilar or generic entry around 8-10 years post-patent expiry could reduce prices by 20–50%.
Key Takeaways
- NDC 60505-4378 (SNDX-5613) is in late-stage development for AML.
- No FDA approval as of now; commercial launch is projected within 2-3 years.
- Market size for AML is approximately $1.2 billion annually, with growth driven by targeted therapies.
- Pricing could range from $20,000 to $30,000/month, similar to existing AML agents.
- Initial revenues could reach $100 million in Year 1; compound to $1 billion in five years under optimistic adoption.
- Competitive landscape and trial outcomes will heavily influence eventual pricing and market share.
FAQs
1. When is NDC 60505-4378 expected to gain FDA approval?
Projected within 2-3 years, contingent on successful phase 2 trial results.
2. How does the pricing compare to existing AML therapies?
Expected to be similar; existing drugs are priced between $16,000 and $28,000 monthly.
3. What factors can influence the final market price?
Efficacy data, safety profile, competitor pricing, patent status, and reimbursement policies.
4. What is the potential revenue impact of biosimilar competition?
Biosimilars could emerge 8-10 years post-patent, potentially halving or reducing prices significantly.
5. How does the AML market growth impact potential for NDC 60505-4378?
The AML market is growing at approximately 8-10% annually, creating upward revenue potential if approval is achieved.
Sources:
- FDA. (2023). Approved Drug Products. [Online] Available at: https://www.accessdata.fda.gov/scripts/cder/daf/
- IQVIA. (2022). U.S. Market Dynamics for Hematology Drugs.
- EvaluatePharma. (2022). Oncology Market Forecast.
- Syndax Pharmaceuticals. (2021). PIPELINE UPDATE.
- Centers for Disease Control and Prevention. (2022). AML Incidence Data.
